# DARETODREAM PROJECT

Transforming treatment and care for kids with blood cancer.

Carisa Almquist, MPH, CHES Patient & Community Outreach Manager Pacific Northwest Region Carisa.Almquist@lls.org 206-957-4585



### AGENDA

- LLS Mission, Resources, and Support
- Dare to Dream Project
- The PedAL Trial
- Discussion, Q&A







### OUR MISSION

The mission of The Leukemia & Lymphoma Society (LLS) is: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families.

We fund **RESEARCH** to advance lifesaving treatments

We drive **ADVOCACY** for policies that protect patient access to lifesaving treatment

We provide patients and families with hope, guidance, education and **SUPPORT** 









### FREE RESOURCES FOR BLOOD CANCER SURVIVORS & THEIR FAMILIES

(800) 955-4572



#### Education

- Education programs (In-person and virtual)
- LLS Health Manager App
- Podcasts & Videos
- Booklets
- Nutrition Consultation

#### **Financial Assistance**

#### Support

- Family Support Groups
- Online Chats
- LLS Community
- Clinical Trial Support Center
- First Connection Program

### **INFORMATION RESOURCE CENTER**



Information Specialists assist patients and their families with financial and social challenges, and give accurate, up-to-date disease, treatment and support information at every stage of the cancer trajectory.

#### Contact:

- (800) 955-4572
- infocenter@lls.org
- Monday Friday, 6am to 6pm PT
- www.LLS.org



#### DARE TO DREAM RESOURCES AND SUPPORT



Side-Effect Management


Effects of Childhood Gancer Treatment on Learni

(800) 955-4572

### **DARE TO DREAM RESOURCES AND SUPPORT**



(800) 955-4572











distribution for every 2, trans. also reveal weaking to the mode and a properties (a.2.12) addition only one, the backwards of the second rate is local weak of American variants found in a simulation of variantic process, since rate and ratios galaxies are provided when a simulation of the second second rate of the second second second second and the second second second second second second second second as a second second second second second second second second second as a second as a second second second second second second second second second as a second second second second second second second second as a second second second second second second second second as a second second second second second second second second as a second second second second second second second second as a second second second second second second second second as a second second second second second second second second as a second second second second second second second second as a second second second second second second second second second as a second second second second second second second second second as a second second second second second second second second as a second as a second secon ALSDOG PLA







### DARE TO DREAM **RESOURCES AND SUPPORT**



#### **Pediatric Education & Support Resources** RESOURCES

The Leukemia & Lymphoma Society offers FREE disease-specific, treatment and support resources in multiple languages. The following are resources we hope are helpful. To access the full list of LLS publications, visit: www.LLS.org/Booklets For additional pediatric specific information please visit www.LLS.org/ChildhoodCancer or call (800) 955-4572 and speak to an Information Specialist.

Introducing The Dare to Dream Project



Prostering in the second Place descentations and P

www.LLS.org/SurvivorshipWorkbook

LLS has produced child-friendly videos CAR T-cell therapy to help answer many questions that a child may have such as:

- What is CAR T-cell therapy? - How does CAR T-cell therapy work?

- How might someone feel after receiving CAR T-cell therapy?





For personalized disease, treatment or support information, please contact an LLS Information Specialist at 800.955.4572 or www.LLS.org/ContactUs





**Pediatric Education & Support Resources** 

CAREGIVING

The Leukemia & Lymphoma Society (LLS) has created a comprehensive set of materials for caregivers of pediatric patients. Caregivers are encouraged to call with guestions or to request additional pediatric resources. For information about these materials and other resources, call an Information Resource Specialists at 800,955,4572 or visit: ww.LLS.org/ContactUs

(800) 955-4572

English and Spanish

Adolescents with Blood Cancer.

CAREGIVERS\* may order a copy of the full workbook, the calendar and the Medi-Teddy and

the Wiskurs Flip Book and Trilogy by calling

Most of these materials are available in both

\*Only caregivers can request a workbook. Visit www.LLS.org/FamilyWorkbook to download a

PDF version of each chapter of Carina for Kids and

#### **Resources for You and Your Child**

The Pediatric Caregiver Workbook \* LLS created this resource full of tools, tips and encouragement for caregivers. Only Caregivers can request a copy of this workbook.



#### Additional Pediatric Resources Include:



Medi Teddy™ teddy bear that fits over IV and feeding tube bags to conceal the contents)



Wiskurs emotions flipbook

Stars Will Twinkle, The Sun Will Shine, a three book series about Olivia's

For personalized disease, treatment or support information, please contact an LLS Information Specialist at 800.955.4572 or www.LLS.org/ContactUs



LEUKEMIA &

### (800) 955-4572





collaborative research and treatments for children's blood cancers, the LLS PedAL Master Clinical Trial, as well as widening our range of free education, 1:1 support services, financial assistance, and advocacy on behalf of all children and their families

CRUMINGS 5

more (no feager)

A 739725-1

www.LLS.org/Booklets

man chile 1-

Pediatric Resources



Dry erase/magnetic calendar



### **THE BLOODLINE WITH LLS**

A PODCAST FOR PATIENTS AND CAREGIVERS

#### Cancer & Caregiving: Navigating My Child's Cancer - Survivorship

NOVEMBER 18, 2021 LEAVE A COMMENT

#### Cancer & Caregiving: Navigating My Child's Cancer - Schooling

NOVEMBER 16, 2021 LEAVE A COMMENT

Join us for our special series where we focus on parent caregivers of children with cancer. In this series we...

#### Training for the Unknown: Jason's Story

NOVEMBER 20, 2019 LEAVE A COMMENT

Listen in as Alicia speaks with Jason Khalipa. Jason is a devoted father, world champion, and global businessman. Jason is a force of nature in the fitness world whose life was turned upside down when his daughter, Ava, was diagnosed with leukemia in 2016 at the age of 4. Jason and his wife, Ashley, dedicated themselves to the fight armed with a positive mindset and an emphasis on physical and mental strength. Join Jason and Alicia as he shares more about how Ava was diagnosed, what their cancer journey taught him not only as a person, but as a father, and how his passion for fitness helped him remain strong and disciplined throughout this new journey.



Jason Khalipa

#### Cancer & Caregiving: Navigating My Child's Cancer – Diagnosis

NOVEMBER 2, 2021 LEAVE A COMMENT

Join us for our special series where we focus on parent caregivers of children with cancer. In this series we will be listening in on a conversation between a social worker and parent caregiver as they navigate the various stages of a child's cancer journey – diagnosis, treatment, post-treatment survivorship, and the child going back to school.





Nancy Cincotta, LCSW, MPhil, CPA Dave Garcia

In the first episode of this series, Nancy

Cincotta, LCSW, MPhil, CPA will talk with parent caregiver, Dave Garcia about the experience of caregiving for his young son, Andy, through the diagnosis stage of acute myeloid leukemia (AML).

#### How Will My Child's Cancer Diagnosis Impact Their Emotions?

MARCH 5, 2020 LEAVE A COMMENT

When you think about a pediatric patient, they are not a child living in a vacuum. They are part of...





### PATTI ROBINSON KAUFMANN FIRST CONNECTION PEER SUPPORT PROGRAM

### (800) 955-4572

The *Patti Robinson Kaufmann First Connection Program* introduces caregivers and adult patients to a trained peer volunteer who has gone through a similar experience.








### LLS SCHOLARSHIP FOR BLOOD CANCER SURVIVORS

### Accepting applications for the 2024-2025 academic year Deadline: October 31, 2023







### QUARTERLY VIRTUAL PEDIATRIC CANCER PROGRAMS

The Power of Play & Creative Therapies for Families Coping with Childhood Cancer Thursday, December 7, 2023, 1:00-2:30pm (EST)

Love, Strength, Support - Sibling Care in the Pediatric Blood Cancer Journey End of Feb/early March 2024 (TBD)

> Summer Fun for the Family May 2024 (TBD)









### THE WHY...

- In 2014, my daughter Anna was diagnosed with Acute Myeloid Leukemia (AML) at age 11
- She spent nearly five months hospitalized continuously
- Four rounds of intense chemotherapy, lasting about a month at a time
- Over 40 blood product transfusions
- Six different infections, including one that put her into septic shock and acute respiratory failure




### IN DECEMBER 2022, SHE CELEBRATED 8 YEARS OF SURVIVORSHIP!












### WE NEED SAFER, LESS TOXIC, MORE EFFECTIVE



۵

Approximately

Of Childhood Cancer Survivors Develop Chronic Health Issues From Treatment Only **5%** Of Oncology Drugs Have Been Approved For First Time Use In Children



### BECAUSE KIDS ARE DIFFERENT

LLS is raising \$175 million over the next five years to fund *The Dare to Dream Project*, a next-level global, groundbreaking approach to:

- Expedite pediatric blood cancer research.
- Bring new, safer treatments to more kids through the PedAL Master Clinical Trial.
- Grow our education and support services as well as drive advocacy for young patients with blood cancer and their families.







### ATTACKING PEDIATRIC BLOOD CANCER FROM

#### LLS PedAL MASTER CLINICAL TRIAL

۵

Test new, safer therapies on kids with acute leukemia who are matched to treatments based on their unique tumor biology in this, the first integrated, global, pediatric AML master clinical trial.

#### RESEARCH

Focus on global collaboration, uniting doctors, pharmaceuticals, and scientists to expedite pediatric blood cancer cures and care.



### POLICY & ADVOCACY

Drive policy to advance research for childhood cancers, break down barriers to care.

### PATIENT EDUCATION & SUPPORT

Expand free education, 1:1 support, and financial services for children and their families.



### TODD MICHAEL COOPER, DO

### SEATLE CHILDREN'S

Professor of Pediatrics | University of Washington Evans Family Endowed Chair in Pediatric Cancer Chair, COG Myeloid Diseases Committee Co-Chair, LLS Pediatric Acute Leukemia Initiative Section Head - Pediatric Oncology | Seattle Children's Cancer and Blood Disorders Center Director – Leukemia/Lymphoma Program











### PEDIATRIC DRUG DEVELOPMENT PARADIGM IS

#### **Current State**

Precision medicine progress in adults not seen for children; children are not miniadults

- Unfavorable business case for pharma industry – cost and operational challenges
- Regulations are onerous and not globally uniform
- Data is siloed and not every child has access to sequencing

### The LLS Dare to Dream Initiative and LLS PedAL



LLS PedAL will ensure dedicated research testing therapies specially targeting the biological drivers of pediatric cancer

Master Trials like Beat AML and LLS PedAL allow testing of multiple agents and bring cost-saving efficiencies


LLS PedAL will create a platform for International cooperation helping pharma companies meet regulatory requirements

Open source Data Commons created through LLS PedAL will consolidate pediatric acute leukemia data from multiple institutions into a single data set, establish a common language and make that data available to researchers worldwide





### DARE TO DREAM THE PEDAL TRIAL



Launch the first global precision medicine clinical trial for pediatric acute leukemia to accelerate better treatments for children with blood cancer

> LLS PedAL will align scientific, medical, corporate and regulatory partners to test multiple targeted theraples simultaneously at up to

200 CLINICAL SITES IN The United States and Around the World.



### PEDAL/EUPAL MISSION & GOALS

#### • SCREEN – Via APAL2020SC and EuPAL registry

• Screen all children with relapsed AML, B-ALL (subset), and T-ALL for therapeutic sub-trial eligibility based on clinical, flow cytometry immunophenotyping, genomic sequencing.

#### DISCOVERY –

- Sample acquisition for correlative biology, target discovery, and biobanking
- ACCESS
  - Partner with pharma, NCI and FDA/EMA, and European study groups (via the EuPAL Foundation) to support drug development platform that achieves regulatory objectives to ensure that children have early access to effective therapies
  - Partner with LLS Navigators to navigate compassionate use access of potentially beneficial agents for those that do not have other trial/therapeutic options

#### • CHANGE –

• Improve post-relapse data collection to inform changes in primary outcome measures and toxicity definitions that better reflect the realities of routine care for children with relapsed leukemia



### DARE TO DREAM BUILDING STANDARDIZED RESOURCES



#### **Data Commons**


- Provides a shared platform to aggregate data
- Ensures consistency in data reporting for doctors, nurses, and researchers to facilitate research progress
- Enables researchers to detect meaningful patterns and drive innovation using a large, uniform data set

**GEARBOx** (Genomic Eligibility Algorithm at Relapse for Better Outcomes)

- Decision support tool for clinicians and nurse navigators
- Web-based tool that uses patient data to identify appropriate trials rapidly and accurately




#### How the LLS PedAL Master Clinical Trial Works



### DARE TO DREAM THE PEDAL TRIALS IN THE PNW







- Seattle Children's Hospital
- Mary Bridge Children's Hospital and Health Center
- Madigan Army Medical Center
- Providence Sacred Heart Medical Center and Children's Hospital
- Providence Alaska Medical Center
- OHSU Doernbecher Children's
- Randall Children's Hospital at Legacy Emanuel



#### APAL2020SC PEDIATRIC ACUTE LEUKEMIA (PEDAL) SCREENING TRIAL – DEVELOPING NEW THERAPIES FOR RELAPSED LEUKEMIAS

Michele Redell – Study Chair Maureen O'Brien – Study Vice-Chair



170+ approved sites (Thanks! High Impact Initiative)

74 sites have enrolled at least 1 patient


6 in Canada; 1 in Australia

181 patients enrolled, 133 confirmed (73%)

Myeloid Diagnoses (73%)		Lymphoid Diagnoses (27%)	
AML relapsed/refractory	86	B-ALL 1 <sup>st</sup> relapse with KMT2Ar	5
Myeloid Leukemia of DS r/r	2	B-ALL 2 <sup>nd</sup> relapse no KMT2Ar	19
Treatment-related AML	9	T-ALL relapsed/refractory	7
		MPAL relapsed/refractory	5



### PEDAL/EUPAL – EUROPEAN AND NORTH AMERICAN





### UNIFYING EFFORTS ACROSS SECTORS, SCIENTIFIC

#### LLS PEDAL: OUR STRATEGIC APPROACH





### WHAT ARE THE DIRECT IMPACTS OF THE DARE TO

- Access to the most innovative targeted therapies
  - LLS navigators
  - Clinical trials leading to future approvals and unlimited access

### Knowledge

• Provides critical biologic information for targeted therapies

### Discovery

 Provides a source for rare and vital samples at relapse to identify new targets and therapies



### PedAL GLOBAL MASTER CLINICAL TRIAL

## It is **bold**. It is game changing. It is **global**. It is happening.



# DISCUSSION & QUESTIONS



*Contact our Information Specialists at* (800) 955-4572 for additional resources!

Join LLS In Supporting The Accelerating Kids' Access to Care Act! Learn more here:

